EANM procedure guidelines for brain neurotransmission SPECT using 123I-labelled dopamine transporter ligands, version 2

No abstract is available for this paper.

• Publication year

  2010

• Venue

  European Journal of Nuclear Medicine and Molecular Imaging

• Publication date

  2010-02-01

• Fields of study

  Medicine, Physics

• Identifiers
  DOI 10.1007/s00259-009-1267-xPMID 19838702
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Les « nouveaux » radiopharmaceutiques

  2008cited by this paper
• Comparison between a dual-head and a brain-dedicated SPECT system in the measurement of the loss of dopamine transporters with [123I]FP-CIT

  2008cited by this paper
• Decreased dopamine transporter availability in male smokers -- a dual isotope SPECT study.

  2008cited by this paper
• Dopamine transporter imaging with [123I]FP-CIT SPECT: potential effects of drugs

  2008cited by this paper
• Reply: Role of DAT SPECT in the diagnostic work‐up of Parkinsonism

  2008cited by this paper
• Role of DAT‐SPECT in diagnostic work‐up of Parkinsonism

  2008cited by this paper
• Meta-analysis of the literature on diagnostic accuracy of SPECT in parkinsonian syndromes

  2007cited by this paper
• The basal ganglia matching tools package for striatal uptake semi-quantification: description and validation

  2007cited by this paper
• Validation of a Standardized Normalization Template for Statistical Parametric Mapping Analysis of 123I-FP-CIT Images

  2007cited by this paper
• Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy

  2007cited by this paper
• Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study.

  2007cited by this paper
• Clinical testing of an optimized software solution for an automated, observer-independent evaluation of dopamine transporter SPECT studies.

  2005cited by this paper
• Is iterative reconstruction an alternative to filtered backprojection in routine processing of dopamine transporter SPECT studies?

  2005cited by this paper
• The effect of levodopa therapy on dopamine transporter SPECT imaging with 123I-FP-CIT in patients with Parkinson’s disease

  2005influential reference
• Levodopa and the progression of Parkinson's disease.

  2004cited by this paper
• The dosimetry of iodine-123 labelled 2β-carbomethoxy-3β-(4-iodophenyl)tropane

  2004cited by this paper
• Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies.

  2004cited by this paper
• Quantitative accuracy of dopaminergic neurotransmission imaging with (123)I SPECT.

  2003cited by this paper
• European Association of Nuclear Medicine procedure guidelines for brain neurotransmission SPET using (123)I-labelled dopamine D(2) transporter ligands.

  2002cited by this paper
• [123I]beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression.

  2001cited by this paper
• Brain SPECT of dopaminergic neurotransmission: a new tool with proved clinical impact.

  2001cited by this paper
• Imaging of the dopaminergic system in parkinsonism with SPET

  2001cited by this paper
• Brain radioligands--state of the art and new trends.

  2001cited by this paper
• [123I]β-CIT SPECT imaging assessment of the rate of Parkinson’s disease progression

  2001cited by this paper
• Brain SPECT of dopaminergic neurotransmission: a new tool with proved clinical impact.

  2001cited by this paper
• Clinical applications of single photon emission tomography in neuromedicine

  2000cited by this paper
• Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]‐FP‐CIT SPECT imaging: The [123I]‐FP‐CIT study group

  2000cited by this paper
• Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group.

  2000cited by this paper
• Correlation of Parkinson's disease severity and duration with 123I‐FP‐CIT SPECT striatal uptake

  2000cited by this paper
• Clinical applications of single photon emission tomography in neuromedicine

  2000cited by this paper
• One-day protocol for imaging of the nigrostriatal dopaminergic pathway in Parkinson's disease by [123I]FPCIT SPECT.

  1999cited by this paper
• Influence of high-energy photons on the spectrum of iodine-123 with low- and medium-energy collimators: consequences for imaging with 123I-labelled compounds in clinical practice

  1999cited by this paper
• Quantification and visualization of defects of the functional dopaminergic system using an automatic algorithm.

  1999cited by this paper
• [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease.

  1997cited by this paper
• Human biodistribution and dosimetry of [123I]FP-CIT: a potent radioligand for imaging of dopamine transporters

  1997cited by this paper
• [sup 123 I] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease

  1996cited by this paper
• [123I] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease.

  1996cited by this paper
• Whole-body biodistribution, radiation absorbed dose and brain SPECT imaging with iodine-123-beta-CIT in healthy human subjects.

  1994cited by this paper
• The dosimetry of iodine-123 labelled 2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane.

  1994cited by this paper

• Toward Harmonizing Quantification of Dopamine Neuron Imaging Biomarkers in Parkinson's Disease: The Centamine Scale.

  2026cites this paper
• Monte Carlo Based Validation of Quantitative Accuracy in I-123 Brain SPECT Through Comparative Evaluation of Gamma Camera Systems

  2026cites this paper
• "Summertime sadness": Striatal dopamine binding decreases during warmer seasons in patients with severe depression.

  2026cites this paper
• Functional Neuroimaging in Clinical Neurology: A Comprehensive Review of Commonly Used Modalities

  2025cites this paper
• Susceptibility and diffusion MRI biomarkers predict development of Parkinsonism in iRBD

  2025cites this paper
• Stability and Accuracy of a Diagnosis of Parkinson Disease Over 10 Years

  2025cites this paper
• Colour discrimination deficit in REM sleep behavior disorder: an analysis of dopaminergic depletion, cognition, and brain morphology

  2025cites this paper
• Increased frontal [123I]FP-CIT binding in Parkinson’s disease patients with self-reported REM sleep behavior disorder

  2025cites this paper
• Molecular connectivity studies in neurotransmission: a scoping review

  2025cites this paper
• Development and in silico imaging trial evaluation of a deep‐learning‐based transmission‐less attenuation compensation method for DaT SPECT

  2025cites this paper
• Central Nervous System Nuclear Imaging.

  2025cites this paper
• Accelerating imaging: deep learning for enhanced 123I-ioflupane SPECT efficiency.

  2025cites this paper
• Development and in silico imaging trial evaluation of a deep-learning-based transmission-less attenuation compensation method for DaT SPECT.

  2025cites this paper
• Striatal dopaminergic patterns and clinical features in frontotemporal dementia

  2025cites this paper
• Magnetic susceptibility components reveal different aspects of neurodegeneration in alpha-synucleinopathies

  2025cites this paper
• Dopaminergic deficits along the spectrum of Alzheimer’s disease

  2025cites this paper
• Automatic analysis of eyelid movement in de-novo Parkinson’s disease

  2025cites this paper
• Combining QSAR and Molecular Docking for the Methodological Design of Novel Radiotracers Targeting Parkinson’s Disease

  2025cites this paper
• Hyperparameter-controlled regularized reconstruction method based on object structure and acquisition conditions in SPECT

  2025influential citation
• [18F]FE‐PE2I PET is a diagnostic tool in dementia with Lewy bodies

  2025cites this paper
• The Utilization and Impact of Dopamine Transporter Imaging in Diagnosing Movement Disorders at a Tertiary Care Hospital in Greece

  2025cites this paper
• Exploring glymphatic system alterations in iRBD and Parkinson’s disease using automated DTI-ALPS analysis

  2025cites this paper
• Unveiling Cortical Criticality Changes along the Prodromal to the Overt Continuum of Alpha-Synucleinopathy

  2025cites this paper
• MRI susceptibility map weighted imaging (SMWI) as a neurodegeneration biomarker in the prodromal to overt alpha-synucleinopathy continuum

  2025cites this paper
• Hand muscle strength in Parkinson's disease: A Sarcopenic epiphenomenon or a meaningful biomarker?

  2025cites this paper
• Smartphone-based prediction of dopaminergic deficit in prodromal and manifest Parkinson’s disease

  2025cites this paper
• Performance of 123I‐ioflupane SPECT striatal binding in dementia with Lewy bodies

  2025cites this paper
• Fully automatic categorical analysis of striatal subregions in dopamine transporter SPECT using a convolutional neural network

  2025cites this paper
• I123‐FP‐CIT (DaTSCAN) SPECT beyond the Most Common Causes of Parkinsonism: A Systematic Review

  2024cites this paper
• Neuropathologic Validation and Diagnostic Accuracy of Presynaptic Dopaminergic Imaging in the Diagnosis of Parkinsonism.

  2024cites this paper
• Insular monoaminergic deficits in prodromal α‐synucleinopathies

  2024cites this paper
• Dietary Caffeine and Brain Dopaminergic Function in Parkinson Disease

  2024cites this paper
• Preclinical evaluation of [18F]FP-CIT, the radiotracer targeting dopamine transporter for diagnosing Parkinson’s disease: pharmacokinetic and efficacy analysis

  2024cites this paper
• Whole brain pattern of iron accumulation in REM sleep behavior disorder

  2024cites this paper
• Dopaminergic dysfunction in the left putamen of patients with major depressive disorder.

  2024cites this paper
• Comparison of quantitative REM without atonia parameters in isolated REM sleep behavior disorder and early untreated Parkinson's disease.

  2024cites this paper
• GMP production of [18F]FE-PE2I on a TRACERLab FX2 N synthesis module, a radiotracer for in vivo PET imaging of the dopamine transport

  2024cites this paper
• Clinical correlates of dopamine transporter availability in cross-sectional and longitudinal studies with [18F]FE-PE2I PET: independent validation with new insights

  2024cites this paper
• Marked Decreased Tracer Binding in 123I-FP-CIT SPECT Scans From Lisdexafetamine Dismesylate Interaction: A Case Report

  2024cites this paper
• Striatal Dopaminergic Function and Motor Slowing in Essential Tremor Plus

  2024cites this paper
• Presynaptic Dopaminergic Imaging Characterizes Patients with REM Sleep Behavior Disorder Due to Synucleinopathy

  2024cites this paper
• Thai national guideline for nuclear medicine investigation in movement disorders: Nuclear medicine society of Thailand, the neurological society of Thailand, and Thai medical physicist society collaboration

  2024cites this paper
• Age and gender effects on striatal dopamine transporter density and cerebral perfusion in individuals with non-degenerative parkinsonism: a dual-phase 18F-FP-CIT PET study

  2024cites this paper
• DaTSCAN® dilution with 0.9% NaCl - A stability evaluation.

  2023cites this paper
• Specific Binding Ratio Estimation of [123I]-FP-CIT SPECT Using Frontal Projection Image and Machine Learning

  2023cites this paper
• Automated identification of uncertain cases in deep learning-based classification of dopamine transporter SPECT to improve clinical utility and acceptance

  2023cites this paper
• Evaluation of Collimators in a High-Resolution, Whole-Body SPECT/CT Device with a Dual-Head Cadmium–Zinc–Telluride Detector for 123I-FP-CIT SPECT

  2023cites this paper
• TremorSoft: An decision support application for differential diagnosis between Parkinson's disease and essential tremor

  2023cites this paper
• Reliability and validity of visual analysis of [18F]FE-PE2I PET/CT in early Parkinsonian disease

  2023cites this paper
• Stereotactical normalization with multiple templates representative of normal and Parkinson-typical reduction of striatal uptake improves the discriminative power of automatic semi-quantitative analysis in dopamine transporter SPECT

  2023cites this paper
• Biomarkers of diagnosis, prognosis, pathogenesis, response to therapy: Convergence or divergence? Lessons from Alzheimer's disease and synucleinopathies.

  2023cites this paper
• No impact of attenuation and scatter correction on the interpretation of dopamine transporter SPECT in patients with clinically uncertain parkinsonian syndrome

  2023cites this paper
• A systematic review of the potential effects of medications and drugs of abuse on dopamine transporter imaging using [123I]I-FP-CIT SPECT in routine practice

  2023cites this paper
• Dopamine transporter SPECT imaging in Parkinson’s disease and atypical Parkinsonism: a study of 137 patients

  2023cites this paper
• Serum but not cerebrospinal fluid levels of allantoin are increased in de novo Parkinson’s disease

  2023cites this paper
• Quantitative [123]I-Ioflupane DaTSCAN single-photon computed tomography-computed tomography in Parkinsonism

  2023cites this paper
• Neurological Insights into Sleep Disorders in Parkinson’s Disease

  2023cites this paper
• [^18F]-FDopa positron emission tomography imaging in corticobasal syndrome

  2023cites this paper
• Combining Neuropsychological Assessment with Neuroimaging to Distinguish Early-Stage Alzheimer’s Disease from Frontotemporal Lobar Degeneration in Non-Western Tonal Native Language-Speaking Individuals Living in Taiwan: A Case Series

  2023cites this paper
• Automated video-based assessment of facial bradykinesia in de-novo Parkinson’s disease

  2022cites this paper
• Metabolic brain pattern in dementia with Lewy bodies: Relationship to Alzheimer’s disease topography

  2022cites this paper
• Combination of compressed sensing-based iterative reconstruction and offset acquisition for I-123 FP-CIT SPECT: a simulation study

  2022influential citation
• Linguistic Abnormalities in Isolated Rapid Eye Movement Sleep Behavior Disorder

  2022cites this paper
• [18F]FE-PE2I PET is a feasible alternative to [123I]FP-CIT SPECT for dopamine transporter imaging in clinically uncertain parkinsonism

  2022cites this paper
• Articulatory undershoot of vowels in isolated REM sleep behavior disorder and early Parkinson’s disease

  2022cites this paper
• Diagnostic value of micrographia in Parkinson’s disease: a study with [123I]FP-CIT SPECT

  2022cites this paper
• Increased Transferrin Sialylation Predicts Phenoconversion in Isolated REM Sleep Behavior Disorder

  2022cites this paper
• Dopamine transporter single-photon emission computed tomography-derived radiomics signature for detecting Parkinson’s disease

  2022cites this paper
• Assessment of different regions of interest-based methods for [99mTc]Tc DAT-SPECT quantification using an anthropomorphic striatal phantom

  2022cites this paper
• Responsivity of the Striatal Dopamine System to Methylphenidate—A Within-Subject I-123-β-CIT-SPECT Study in Male Children and Adolescents With Attention-Deficit/Hyperactivity Disorder

  2022cites this paper
• Synthesis of Radioiodinated Compounds. Classical Approaches and Achievements of Recent Years

  2022cites this paper
• An ordinal CNN approach for the assessment of neurological damage in Parkinson's disease patients

  2021cites this paper
• Cognitive Decline in Parkinson’s Disease: A Subgroup of Extreme Decliners Revealed by a Data-Driven Analysis of Longitudinal Progression

  2021cites this paper
• In vivo human molecular neuroimaging of dopaminergic vulnerability along the Alzheimer’s disease phases

  2021influential citation
• 123I-Ioflupane SPECT and 18F-FDG PET Combined Use in the Characterization of Movement and Cognitive Associated Disorders in Neurodegenerative Diseases.

  2021cites this paper
• A tissue-fraction estimation-based segmentation method for quantitative dopamine transporter SPECT.

  2021cites this paper
• Pharmacokinetic Modeling of 18F-FDOPA PET in the Human Brain for Early Parkinson’s Disease

  2021influential citation
• Dysprosody in Isolated REM Sleep Behavior Disorder with Impaired Olfaction but Intact Nigrostriatal Pathway

  2021cites this paper
• Cuneus/precuneus as a central hub for brain functional connectivity of mild cognitive impairment in idiopathic REM sleep behavior patients

  2021cites this paper
• Explainable AI to improve acceptance of convolutional neural networks for automatic classification of dopamine transporter SPECT in the diagnosis of clinically uncertain parkinsonian syndromes

  2021cites this paper
• Improved Performance of a Multipinhole SPECT for DAT Imaging by Increasing Number of Pinholes at the Expense of Increased Multiplexing

  2021cites this paper
• Clinical value of machine learning-based interpretation of I-123 FP-CIT scans to detect Parkinson’s disease: a two-center study

  2021cites this paper
• Faster Region-Based Convolutional Neural Network in the Classification of Different Parkinsonism Patterns of the Striatum on Maximum Intensity Projection Images of [18F]FP-CIT Positron Emission Tomography

  2021cites this paper
• Clinical and Dopamine Transporter Imaging Trajectories in a Cohort of Parkinson's Disease Patients with GBA Mutations

  2021cites this paper
• Phase and amplitude electroencephalography correlations change with disease progression in people with idiopathic rapid eye-movement sleep behavior disorder

  2021cites this paper
• Stratification Tools for Disease‐Modifying Trials in Prodromal Synucleinopathy

  2021cites this paper
• Phase and amplitude correlations change with disease progression in idiopathic Rapid eye-movement sleep behavior disorder patients

  2021cites this paper
• Defining Speech Subtypes in De Novo Parkinson Disease

  2021cites this paper
• Radiopharmaceuticals in Clinical Diagnosis and Therapy

  2021cites this paper
• Acquisition count dependence of the specific binding ratio in 123I-FP-CIT SPECT

  2021cites this paper
• Diagnostic accuracy of glabellar tap sign for Parkinson’s disease

  2021cites this paper
• Case Report: Bupropion Reduces the [123I]FP-CIT Binding to Striatal Dopamine Transporter

  2021cites this paper
• Data-driven identification of diagnostically useful extrastriatal signal in dopamine transporter SPECT using explainable AI

  2021cites this paper
• Responsivity of the striatal dopamine system to methylphenidate - a within-subject I-123-β-CIT-SPECT study in children and adolescents with Attention-Deficit/Hyperactivity Disorder

  2021cites this paper
• Ordinal classification of the affectation level of 3D-images in Parkinson diseases

  2021cites this paper
• Automated speech analysis in early untreated Parkinson's disease: Relation to gender and dopaminergic transporter imaging

  2021cites this paper
• A novel supervised machine learning algorithm to detect Parkinson’s disease on its early stages

  2021cites this paper
• Quantitative Monte Carlo-based brain dopamine transporter SPECT imaging

  2020cites this paper
• Simplified quantification of [18F]FE-PE2I PET in Parkinson’s disease: Discriminative power, test–retest reliability and longitudinal validity during early peak and late pseudo-equilibrium

  2020cites this paper
• Performance evaluation of gamma cameras with multi-pinhole collimators for brain SPECT imaging

  2020cites this paper